Roche “Avenue” BP29647

Status: Ongoing, but not recruiting participants.

ClinicalTrials.gov Identifier: NCT02484690

BP29647: A Phase III, Multi-Center, Multi-Dose, Double-Masked, Parallel Group to investigate the Safety and Tolerability of RO6867461 in patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration.

Condition: Choroidal Neovascularization

Study Type: Interventional

Duration: 36 weeks

Eligibility:

  • Ages: 50 years and older
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information on this study, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.